<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129260">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01675076</url>
  </required_header>
  <id_info>
    <org_study_id>UOHI-05</org_study_id>
    <nct_id>NCT01675076</nct_id>
  </id_info>
  <brief_title>Strategy of Continued Versus Interrupted Dabigatran at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events</brief_title>
  <acronym>BRUISECONTROL2</acronym>
  <official_title>A Randomized Controlled Trial to Investigate Whether a Strategy of Continued Versus Interrupted Dabigatran at the Time of Device Surgery, in Patients With Moderate to High Risk of Arterial Thrombo-embolic Events, Leads to a Reduction in the Incidence of Clinically Significant Hematoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ottawa Heart Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Ottawa Heart Institute</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the best strategy to manage Dabigatran at the time
      of pacemaker or defibrillator surgery.  The Investigators hypothesize that performing device
      surgery without interruption of Dabigatran will result in a reduced rate of clinically
      significant hematoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, open-label, randomized trial, with 1:1 randomization to either
      continued Dabigatran or interrupted Dabigatran in patients at moderate to high risk of
      arterial thrombo-embolic events who require device surgery.

      All patients in the study will be treated with Dabigatran for at least 5 days prior to
      surgery. Regardless of the chronic dose, all patients will receive Dabigatran 110 mg BID for
      5 days prior to device surgery and for the 5 days following surgery.  The peri-operative
      management of Dabigatran 110 mg BID is randomized to the following:

        1. Interrupted Dabigatran

             -  based on renal function, patients will discontinue Dabigatran 1 day before surgery
                if GFR &gt; 50 mL/min, and 2 days before surgery if GFR is 30-50 mL/min.

             -  Dabigatran will be resumed at the next regular dose time, at least 24 hours after
                the end of surgery.

        2. Continued Dabigatran

             -  patients will continue on Dabigatran 110 mg BID throughout

             -  patients will have an aPTT measured at trough (within 2 hours prior to next
                dose)once within 5 days prior to the surgery.  If the aPTT is &gt; 2.5 times the
                upper limit of normal, the dose of Dabigatran will be held on the morning of
                surgery.

      All patients will have clinical lab testing of serum creatinine, CBC, INR, aPTT, thrombin
      clotting time (TCT) and Hemoclot test on the day of surgery.

      Patients will be seen post-op on the day of their surgery for assessment of the surgical
      site and each day throughout their hospital stay by a blinded member of the research team.
      A telephone follow-up will be done on day 3-4 post surgery by an unblinded team member.  All
      patients are seen 1-2 weeks post-op at their first routine post-op device clinic visit, for
      surgical site assessment by the blinded assessor and to complete Quality of Life
      questionnaires. Patients will be seen for assessment in the case of any bleeding or
      development of pocket swelling or hematoma. Patients developing a hematoma will be followed
      until resolution of the hematoma.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Clinically significant hematoma</measure>
    <time_frame>2 weeks post-op or until resolution of hematoma</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Defined as:
Hematoma requiring re-operation
- Defined as a hematoma that continues to expand despite all appropriate non-operative measures, or is producing impending or actual wound breakdown or skin necrosis. Minor hematomas that are evacuated at the time of other re-operation (eg. for lead repositioning) are not considered as a primary outcome.
or
Hematoma resulting in prolongation of hospitalization
- Defined as extended hospitalization or rehospitalization for &gt; 24 hours, post index surgery, primarily due to hematoma.
or
Hematoma requiring interruption of anti-coagulation. - Defined as reversal or intentional withholding of all anticoagulation, in response to wound hematoma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of major peri-operative bleeding events and thrombo-embolic events</measure>
    <time_frame>2 weeks post-op</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Each of the components of the primary outcome
Composite of all other major peri-operative bleeding events defined as:
hemothorax
cardiac tamponade
significant pericardial effusion
Thrombo-embolic events defined as:
transient ischemic attack
stroke
deep venous thrombosis
pulmonary embolism
peripheral embolus to limb
peripheral embolus to other major organ
All cause mortality
Cost utilization
Patient quality of life and peri-operative pain, and satisfaction</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">846</enrollment>
  <condition>Hematoma</condition>
  <arm_group>
    <arm_group_label>Continued Dabigatran</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>- Patients continue on Dabigatran 110 mg BID throughout</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Interrupted Dabigatran</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Discontinue Dabigatran 1 day before surgery if GFR &gt; 50 mL/min or discontinue 2 days before surgery if GFR 30-50 mL/min
Resume Dabigatran at next regular dose timing at least 24 hours after the end of surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran</intervention_name>
    <arm_group_label>Continued Dabigatran</arm_group_label>
    <arm_group_label>Interrupted Dabigatran</arm_group_label>
    <other_name>Pradax</other_name>
    <other_name>Pradaxa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  any patient undergoing device surgery (ie. de novo device implant or pulse generator
             change or lead replacement or pocket revision)

          -  receiving Dabigatran for at least 5 days prior to surgery

          -  non-rheumatic AF and/or atrial flutter and CHADS2 score greater than or equal to 2

        Exclusion Criteria:

          -  unable ot unwilling to provide informed consent

          -  history of noncompliance of medical therapy

          -  active device infection

          -  included in another clinical trial

          -  GFR &lt; 30 mL/min

          -  contraindication to Dabigatran

          -  rheumatic valvular disease with hemodynamically significant valve lesion

          -  mechanical heart valve
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Birnie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Ottawa Heart Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vidal Essebag, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeff Healey, MD</last_name>
    <role>Study Chair</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen MacDonald, RN BPE</last_name>
    <phone>613-798-5555</phone>
    <phone_ext>17077</phone_ext>
    <email>kmacdonald@ottawaheart.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Foothills Medical Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Glen Sumner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences General Campus</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jeff Healey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southlake Regional Health Centre</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 2P9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Atul Verma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen MacDonald, RN</last_name>
      <phone>613-798-5555</phone>
      <phone_ext>17077</phone_ext>
      <email>kmacdonald@ottawaheart.ca</email>
    </contact>
    <investigator>
      <last_name>Pablo Nery, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Sacre-Coeur</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Giuliano Becker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre/Montreal General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vidal Essebag, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Universite de Montreal (CHUM), Hotel Dieu</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Benoit Coutu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Sherbrooke-Hopital Fleurimont</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>JiH 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Felix Ayala-Paredes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire de Cardiologie et de Pneumologie de Quebec</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Francois Philippon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 13, 2014</lastchanged_date>
  <firstreceived_date>August 27, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hematoma</keyword>
  <keyword>Dabigatran</keyword>
  <keyword>Device surgery</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hematoma</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
